Developer docs
API playgroundTry for free, no card

Search company profiles

Lucid Scientific

Full company profile

uuid0002o1e

Namestring
Lucid Scientific
Legal namestring
Lucid Scientific, Inc.
Websiteurl
lucidsci.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Lucid Scientific, Inc. is a privately held biotechnology instrumentation company headquartered in Atlanta, Georgia, founded in 2012 and Delaware-incorporated. The company designs, develops, and sells Resipher, a non-invasive metabolic cell analyzer that converts standard 96-well plates into real-time, dynamic oxygen consumption readers. Resipher enables continuous bioenergetic profiling — measuring mitochondrial electron transport chain function, fatty acid oxidation substrate metabolism, ATP-linked respiration, spare capacity, and proton leak — across experiments lasting days to months without disrupting standard incubator workflows. The platform supports 2D monolayers, 3D organoids, tissue slices, embryos, and whole organisms in multiple plate formats.

The company targets three primary customer segments: academic research institutions conducting metabolic and bioenergetics studies, pharmaceutical and biotechnology companies using metabolic profiling for drug discovery and preclinical toxicity testing, and contract research organizations providing metabolic analysis services. Its go-to-market is a direct sales motion combining website-enabled purchases ('Buy today', 'Purchase a system') and enterprise demo requests, supported by HubSpot-integrated lead management and a digital content strategy centered on publications, how-to videos, and technical documentation. Revenue is generated primarily through Resipher hardware sales with an implied recurring component from plates and related consumables; pricing is not publicly disclosed.

Lucid Scientific has raised approximately $10.1 million in cumulative funding across small Georgia Research Alliance grants (2018–2019), a $3M seed round in 2020 led by Dynamk Capital, and a $7M Series A in September 2023 led by IAG Capital Partners. The company operates with 11–50 employees and has no disclosed partnerships, acquisitions, or AI/ML capabilities.

Short descriptiontext

Lucid Scientific designs and sells Resipher, a non-invasive metabolic cell analyzer that turns standard 96-well plates into continuous oxygen consumption readers for bioenergetic research, serving academic, pharmaceutical/biotech, and CRO customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAtlanta, United States
HQ citystring
Atlanta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell metabolism analysis, oxygen consumption readers, bioenergetic profiling instruments, metabolic cell analyzers, laboratory research equipment
Industry1 code
PRIMARYHLAGAIAB
Mass Spectrometry & Spectroscopy Instruments
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Laboratory Analytical Instruments
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Resipher System Sales
TypeHardware Sales
Description

Sale of the Resipher non-invasive metabolic cell analyzer hardware system. The product turns standard 96-well plates into precise dynamic oxygen consumption readers for bioenergetic research applications.

lucidsci.com
2Consumables and Accessories
TypeSubscription Recurring
Description

Implied recurring revenue from plates and related consumables for ongoing laboratory research workflows.

lucidsci.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Resipher
Description

Non-invasive metabolic cell analyzer for continuous bioenergetic profiling of mitochondrial ETC function, FAO substrate metabolism, and long-term baselines for stable basal respiration.

lucidsci.com
+1 more record
Core offering1 text field

Lucid Scientific designs, develops, and sells Resipher, a non-invasive metabolic cell analyzer that converts standard 96-well plates into dynamic oxygen consumption readers for continuous bioenergetic profiling. The instrument measures mitochondrial ETC function, FAO substrate metabolism, ATP-linked respiration, spare capacity, and proton leak over experiments lasting days to months, integrating directly into standard laboratory incubator workflows. The company sells hardware systems with associated consumables and accessories to academic, pharmaceutical, and biotech research customers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Lucid Scientific offers a single unified product, Resipher, a continuous bioenergetics platform for non-invasive metabolic cell analysis. Resipher enables bioenergetic profiling of mitochondrial ETC function and FAO substrate metabolism using standard 96-well plates, with the ability to measure functional parameters including ATP-linked respiration, spare capacity, and proton leak over experiments lasting days to months.

Product and service1 record
1Resipher
CategoryLaboratory analytical instruments
Description

Non-invasive metabolic cell analyzer that converts standard 96-well plates into precise dynamic oxygen consumption readers, enabling continuous bioenergetic profiling of mitochondrial ETC function, FAO substrate metabolism, ATP-linked respiration, spare capacity, and proton leak over days-to-months-long experiments for academic, pharmaceutical, biotech, and CRO researchers.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Agilent owns the Seahorse XF analyzer, the dominant instrument for real-time cellular bioenergetics measurement. It is the most direct competitor to Lucid Scientific's Resipher, targeting the same academic and pharma customers with a similar oxygen consumption-based value proposition and a much larger installed base and consumables catalog.

TypeDirect peer
Description

Nanion manufactures the Oroboros O2k high-resolution respirometer for cellular and mitochondrial oxygen consumption analysis. It directly competes with Resipher in real-time metabolic profiling and shares a focus on research-grade instrumentation for bioenergetics applications.

TypeBroad incumbent
Description

Bruker is a large analytical instruments company with a portfolio spanning mass spectrometry, NMR, and cellular/molecular analysis tools. While not focused exclusively on real-time cell metabolism, it competes in the broader life science research instruments market and serves overlapping academic and pharma customers.

TypeBroad incumbent
Description

Thermo Fisher is the largest life sciences tools company, offering cell analysis instruments, microplate readers, and consumables that overlap with Lucid Scientific's target market. Its CellInsight and similar platforms represent adjacent competition for cell-based metabolic and phenotypic assays.

TypeBroad incumbent
Description

Sartorius is a major bioprocessing and cell analysis company with products spanning cell line development, live-cell analysis (Incucyte), and lab consumables. Its broader portfolio of cell-based analytical tools competes for the same biopharma R&D budgets that fund Resipher purchases.

TypeBroad incumbent
Description

Revvity (formerly PerkinElmer's Life Sciences business) provides a wide range of life science research tools including cell-based assays, imaging, and analytical reagents. It addresses overlapping customer needs in drug discovery and translational research.

TypeEmerging player
Description

Promega develops cell-based luminescence and fluorescence assay tools, including metabolism-relevant readouts that compete at the assay level with Resipher's bioenergetic measurements. It serves the same academic and pharma research segments with a focus on assay reagents rather than dedicated instruments.

TypeDirect peer
Description

PreSens is a specialty manufacturer of optical oxygen and pH sensors, including microplate-based respirometry systems that compete directly with Resipher's optical oxygen consumption measurement technology in cell metabolism research.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lucid Scientific

Laboratory Analytical Instrumentslucidsci.com

Lucid Scientific designs and sells Resipher, a non-invasive metabolic cell analyzer that turns standard 96-well plates into continuous oxygen consumption readers for bioenergetic research, serving academic, pharmaceutical/biotech, and CRO customers.

What Lucid Scientific does

Lucid Scientific, Inc. is a privately held biotechnology instrumentation company headquartered in Atlanta, Georgia, founded in 2012 and Delaware-incorporated. The company designs, develops, and sells Resipher, a non-invasive metabolic cell analyzer that converts standard 96-well plates into real-time, dynamic oxygen consumption readers. Resipher enables continuous bioenergetic profiling — measuring mitochondrial electron transport chain function, fatty acid oxidation substrate metabolism, ATP-linked respiration, spare capacity, and proton leak — across experiments lasting days to months without disrupting standard incubator workflows. The platform supports 2D monolayers, 3D organoids, tissue slices, embryos, and whole organisms in multiple plate formats.

The company targets three primary customer segments: academic research institutions conducting metabolic and bioenergetics studies, pharmaceutical and biotechnology companies using metabolic profiling for drug discovery and preclinical toxicity testing, and contract research organizations providing metabolic analysis services. Its go-to-market is a direct sales motion combining website-enabled purchases ('Buy today', 'Purchase a system') and enterprise demo requests, supported by HubSpot-integrated lead management and a digital content strategy centered on publications, how-to videos, and technical documentation. Revenue is generated primarily through Resipher hardware sales with an implied recurring component from plates and related consumables; pricing is not publicly disclosed.

Lucid Scientific has raised approximately $10.1 million in cumulative funding across small Georgia Research Alliance grants (2018–2019), a $3M seed round in 2020 led by Dynamk Capital, and a $7M Series A in September 2023 led by IAG Capital Partners. The company operates with 11–50 employees and has no disclosed partnerships, acquisitions, or AI/ML capabilities.

Lucid Scientific firmographics

Firmographics
Name
Lucid Scientific
Legal name
Lucid Scientific, Inc.
Website
https://lucidsci.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Lucid Scientific designs and sells Resipher, a non-invasive metabolic cell analyzer that turns standard 96-well plates into continuous oxygen consumption readers for bioenergetic research, serving academic, pharmaceutical/biotech, and CRO customers.
Ownership category
akta.pro rank

Lucid Scientific industry classification

Industry
Product category
Laboratory Analytical Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAIAB
Mass Spectrometry & Spectroscopy Instruments

Keywords

  • Cell metabolism analysis
  • Oxygen consumption readers
  • Bioenergetic profiling instruments
  • Metabolic cell analyzers
  • Laboratory research equipment

Where Lucid Scientific is headquartered

Location

Headquarters

HQ city
Atlanta
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Lucid Scientific business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. Resipher System Sales: Sale of the Resipher non-invasive metabolic cell analyzer hardware system. The product turns standard 96-well plates into precise dynamic oxygen consumption readers for bioenergetic research applications.
  2. Consumables and Accessories: Implied recurring revenue from plates and related consumables for ongoing laboratory research workflows.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Lucid Scientific product offering

Product offering

Core offering

Lucid Scientific designs, develops, and sells Resipher, a non-invasive metabolic cell analyzer that converts standard 96-well plates into dynamic oxygen consumption readers for continuous bioenergetic profiling. The instrument measures mitochondrial ETC function, FAO substrate metabolism, ATP-linked respiration, spare capacity, and proton leak over experiments lasting days to months, integrating directly into standard laboratory incubator workflows. The company sells hardware systems with associated consumables and accessories to academic, pharmaceutical, and biotech research customers.

Product overview

Lucid Scientific offers a single unified product, Resipher, a continuous bioenergetics platform for non-invasive metabolic cell analysis. Resipher enables bioenergetic profiling of mitochondrial ETC function and FAO substrate metabolism using standard 96-well plates, with the ability to measure functional parameters including ATP-linked respiration, spare capacity, and proton leak over experiments lasting days to months.

Differentiator

Problem solved

Functional benefit

Brands

  • Resipher: Non-invasive metabolic cell analyzer for continuous bioenergetic profiling of mitochondrial ETC function, FAO substrate metabolism, and long-term baselines for stable basal respiration.
  • Continuous Bioenergetics

Products and services

  • Resipher Non-invasive metabolic cell analyzer that converts standard 96-well plates into precise dynamic oxygen consumption readers, enabling continuous bioenergetic profiling of mitochondrial ETC function, FAO substrate metabolism, ATP-linked respiration, spare capacity, and proton leak over days-to-months-long experiments for academic, pharmaceutical, biotech, and CRO researchers.

Companies that use Lucid Scientific

Customer profile

Segments3 records

Ideal customer profiles3 records

Lucid Scientific technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Lucid Scientific partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Lucid Scientific competitors and assessment

Company assessment

Direct peers

  • Agilent Technologies: Agilent owns the Seahorse XF analyzer, the dominant instrument for real-time cellular bioenergetics measurement. It is the most direct competitor to Lucid Scientific's Resipher, targeting the same academic and pharma customers with a similar oxygen consumption-based value proposition and a much larger installed base and consumables catalog.
  • Nanion Technologies: Nanion manufactures the Oroboros O2k high-resolution respirometer for cellular and mitochondrial oxygen consumption analysis. It directly competes with Resipher in real-time metabolic profiling and shares a focus on research-grade instrumentation for bioenergetics applications.
  • PreSens Precision Sensing: PreSens is a specialty manufacturer of optical oxygen and pH sensors, including microplate-based respirometry systems that compete directly with Resipher's optical oxygen consumption measurement technology in cell metabolism research.

Broad incumbents

  • Bruker Corporation: Bruker is a large analytical instruments company with a portfolio spanning mass spectrometry, NMR, and cellular/molecular analysis tools. While not focused exclusively on real-time cell metabolism, it competes in the broader life science research instruments market and serves overlapping academic and pharma customers.
  • Thermo Fisher Scientific: Thermo Fisher is the largest life sciences tools company, offering cell analysis instruments, microplate readers, and consumables that overlap with Lucid Scientific's target market. Its CellInsight and similar platforms represent adjacent competition for cell-based metabolic and phenotypic assays.
  • Sartorius AG: Sartorius is a major bioprocessing and cell analysis company with products spanning cell line development, live-cell analysis (Incucyte), and lab consumables. Its broader portfolio of cell-based analytical tools competes for the same biopharma R&D budgets that fund Resipher purchases.
  • Revvity: Revvity (formerly PerkinElmer's Life Sciences business) provides a wide range of life science research tools including cell-based assays, imaging, and analytical reagents. It addresses overlapping customer needs in drug discovery and translational research.

Emerging players

  • Promega Corporation: Promega develops cell-based luminescence and fluorescence assay tools, including metabolism-relevant readouts that compete at the assay level with Resipher's bioenergetic measurements. It serves the same academic and pharma research segments with a focus on assay reagents rather than dedicated instruments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Lucid Scientific social profiles

Digital presence

Lucid Scientific financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lucid Scientific leadership team

Management profile

Number of profiles

Profiles2 records

Lucid Scientific funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lucid Scientific M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lucid Scientific

What does Lucid Scientific do?

Lucid Scientific designs, develops, and sells Resipher, a non-invasive metabolic cell analyzer that converts standard 96-well plates into dynamic oxygen consumption readers for continuous bioenergetic profiling. The instrument measures mitochondrial ETC function, FAO substrate metabolism, ATP-linked respiration, spare capacity, and proton leak over experiments lasting days to months, integrating directly into standard laboratory incubator workflows. The company sells hardware systems with associated consumables and accessories to academic, pharmaceutical, and biotech research customers.

Is Lucid Scientific a public or private company?

Lucid Scientific is a private company. It is classified as venture growth investor backed and is currently operating.

When was Lucid Scientific founded?

Lucid Scientific was founded in 2012. It employs 11 to 50 people.

Where is Lucid Scientific based?

Lucid Scientific is headquartered in Atlanta, United States, in the North America region.

How does Lucid Scientific make money?

Two revenue lines are on record. Resipher System Sales are the primary driver. The others are consumables and Accessories.

Who are Lucid Scientific's main competitors?

Direct peers on record are Agilent Technologies, Nanion Technologies and PreSens Precision Sensing. Broad incumbents are Bruker Corporation, Thermo Fisher Scientific, Sartorius AG and Revvity. Promega Corporation is listed as an emerging player.

Does Lucid Scientific have an API?

No public API is recorded for Lucid Scientific.

What industry is Lucid Scientific in?

Lucid Scientific's product category is Laboratory Analytical Instruments. Its primary akta.pro industry code is HLAGAIAB, Mass Spectrometry & Spectroscopy Instruments. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Lucid Scientific: Life Science Instruments Company Secures $7 MillionLucid Scientific completed a $7 million Series A financing led by IAG Capital Partners, bringing total funding to about $13 million. The proceeds will support production, sales, marketing, and new product advancements, including a fall launch of Resipher hardware and consumables for real-time cell metabolomics.FinSMEsLucid Scientific Raises $7M in Series A FinancingLucid Scientific raised $7M in Series A funding led by IAG Capital Partners, bringing total funding to $13M. The Atlanta-based life science instruments company will use the funds to expand production, sales, marketing, and new product advancements. IAG Venture Partner Dr. Ehsan Jabbarzadeh will join the board.Venture Capital Access OnlineLucid Scientific Secures $7 Million Series A Financing Led by IAG Capital PartnersLucid Scientific has secured $7 million in Series A financing led by IAG Capital Partners to expand production, sales, and marketing capabilities. The company plans to use the funds to support the upcoming launch of new Resipher hardware and consumable products for real-time metabolic analysis. This round brings Lucid's total funding to approximately $13 million.SecSEC FORM DLucid Scientific, Inc. filed a Form D with the Securities and Exchange Commission to report an exempt securities offering under Rule 506(b). The filing indicates that the company has sold approximately $8.9 million of equity securities out of a total offering amount of roughly $9.2 million, with about $280,000 remaining to be sold. This regulatory disclosure was signed by CEO Samuel Walker Inman on September 5, 2023.FinSMEsLucid Scientific Closes $3M Seed FinancingLucid Scientific, an Atlanta-based biotechnology tools company, closed a $3M seed financing led by Dynamk Capital, bringing total funding to about $4.5M. The company will use the funds to expand production, sales, marketing, and product development. Its patented RESIPHER system monitors cellular metabolism via non-invasive optical sensors.PR NewswireLucid Scientific Secures $3 Million in Series Seed Financing Led by Dynamk CapitalLucid Scientific, a biotechnology tools company headquartered in Atlanta, has closed a $3 million Series Seed financing round led by Dynamk Capital, with participation from the Georgia Research Alliance's Venture Fund, bringing total funding to approximately $4.5 million. The capital will fund expansion of production, sales, marketing, and product development for the RESIPHER platform, which converts standard cell culture plates into real-time metabolic monitoring readers for drug discovery and research. Dynamk Capital Managing Partner Dr. Gustavo Mahler will join Lucid Scientific's Board of Directors as part of the transaction.American City Business JournalsLucid Scientific raises $3M in series seed roundLucid Scientific raised $3 million in a series seed round led by Dynamk Capital, bringing total funding to $4.5 million. The biotech tools startup will use the funds to expand commercial activities, production, and hiring. The company launched its RESIPHER product line in spring 2020.VC News DailyLucid Scientific Raises $3M Seed FinancingLucid Scientific has completed a $3 million Series Seed financing round led by Dynamk Capital, bringing its total funding to approximately $4.5 million. The company plans to use the proceeds to expand production, sales, marketing, and product development for its RESIPHER biotechnology tools. Dr. Gustavo Mahler of Dynamk Capital will join Lucid's Board of Directors as part of the deal.